Table 1

Clinic and laboratory data before treatment with rituximab, during hospitalisation, and in the follow-up

	January 28	April 4	April 10	April 17	April 24	May 1	May 8	May 15	May 25	June 6	July 2
RT-PCR		+	+	+	+	+	+	+	+	–	–
IgM-SARS-CoV-2 AU/mL		0.2	0.3	0.2	0.2	0.32	0.23	0.26	0.25	0.32	0.1
IgG-SARS-CoV-2 AU/mL		2.3	2.5	0.7	0.6	0.41	0.21	0.34	9.6	11.6	0.3
CD3+ cells/μL	2452	1802	2387	1238	1341	1156	858	784	778	1356	2078
CD4+ cell/μL	1315	1223	1677	856	736	578	416	389	403	758	905
CD8+ cell/μL	689	531	625	212	578	411	302	305	285	378	1107
CD56+ cell/μL	337	137	129	78	134	98	65	53	89	215	433
CD19+ cell/μL	26	1	3	2	0.2	0.4	0.3	0.6	0.1	0.6	1
CD20+ cell/μL	20	1	2	1	0.5	0.7	0.8	0.4	0.4	0.5	0.1
CD27+ naive cell/μL	22	0.1	0.6	0.6	0.1	0.6	0.4	0.7	0.6	0.3	1
CD27+ memory cell/μL	12	1.3	0.4	0.4	0.4	0.5	0.5	0.7	0.4	0.5	0.1
CD38+ cell/μL	9	0.4	0.5	0.7	0.6	0.3	0.1	0.6	0.6	2.3	1.4
IgG mg/dL	643	689	673	613	518	568	1856	1789	2134	789	637
IgA mg/dL	67	56	79	69	87	73	77	89	78	81	97
IgM mg/dL	71	68	62	56	53	51	89	91	98	101	78
Horovitz Index		108	96	48	51	49	46	56	170	280	300
Echo Score		38	40	38	36	32	38	36	28	14	8
Antimalarials		+	+	+	+	+	+	–	–	–	+
Antiviral treatments		LOP-RIT	LOP-RIT	LOP-RIT					REM	REM
Biological agent			TOC			TOC	IVIG	IVIG	IVIG-CP	CP
Other treatments	PDN MTX	DEX HEP AZI	DEX HEP AZI	DEX HEP AZI	DEX HEP	DEX HEP	DEX HEP MER LIN	DEX HEP MER LIN	DEX HEP	PDN HEP	PDN HEP

Horovitz Index (SpO₂/FiO₂ ratio).
-, absent; +, present; CP, convalescent plasma; DEX, dexamethasone; HEP, heparin; IVIG, intravenous immunoglobulin; LOP-RIT, lopinavir/ritonavir; MER-LIN, meropenem/linezolid; MTX, methotrexate; PDN, prednisone; REM, remdesivir; TOC, tocilizumab.